Epigenetic Therapy of Cancer
Preclinical Models and Treatment Approaches
Peter A Jones editor Michael Lübbert editor
Format:Paperback
Publisher:Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
Published:24th Sep '16
Currently unavailable, and unfortunately no date known when it will be back
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
From the reviews:
“This new book covers the timely topic of epigenetic therapy. … The combination of articles describing the basic science framework of epigenetics and the detailed summaries of clinical trials with epigenetic drugs is attractive for a wide readership, ranging from medical students to scientists who are interested in translational studies to clinicians who work for the direct benefit of cancer patients. … This high-quality book is an excellent overview of the current success and future promise of epigenetic therapy.” (Gerd Pfeifer, Doody’s Book Reviews, May, 2ISBN: 9783662519288
Dimensions: unknown
Weight: unknown
325 pages
Softcover reprint of the original 1st ed. 2014